SML1885
Mitotane
≥98% (HPLC)
別名:
1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]-benzene, 2,4′-DDD, o,p′-DDD
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C14H10Cl4
CAS番号:
分子量:
320.04
UNSPSC Code:
12352200
NACRES:
NA.77
EC Number:
200-166-6
MDL number:
製品名
Mitotane, ≥98% (HPLC)
InChI key
JWBOIMRXGHLCPP-UHFFFAOYSA-N
InChI
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
SMILES string
ClC1=C(C(C(Cl)Cl)C2=CC=C(Cl)C=C2)C=CC=C1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
Mitotane is a selective inhibitor of sterol-Oacyl-transferase 1 (SOAT1), also known as ACAT1, (acyl-coenzyme A cholesterol acyltransferase).
Mitotane is a selective inhibitor of sterol-Oacyl-transferase 1 (SOAT1), also known as ACAT1, (acyl-coenzyme A cholesterol acyltransferase). Mitotane inhibition of SOAT1 in adrenocortical carcinoma cells decreased the formation of cholesteryl esters, which increased free cholesterol levels and caused endoplasmic reticulum (ER) stress, the unfolded protein response, and eventually apoptosis.
signalword
Warning
hcodes
Hazard Classifications
Carc. 2
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Matthias Kroiss et al.
Hormones & cancer, 7(5-6), 345-355 (2016-11-01)
Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clinically used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids. Since mitotane has limited clinical
S Beloribi-Djefaflia et al.
Oncogenesis, 5, e189-e189 (2016-01-26)
Many human diseases, including metabolic, immune and central nervous system disorders, as well as cancer, are the consequence of an alteration in lipid metabolic enzymes and their pathways. This illustrates the fundamental role played by lipids in maintaining membrane homeostasis
Xiangyu Li et al.
iScience, 24(7), 102722-102722 (2021-07-15)
Clear cell renal cell carcinoma (ccRCC) is the most common histological type of kidney cancer and has high heterogeneity. Stratification of ccRCC is important since distinct subtypes differ in prognosis and treatment. Here, we applied a systems biology approach to
Silviu Sbiera et al.
Endocrinology, 156(11), 3895-3908 (2015-08-26)
Adrenocortical carcinoma (ACC) is a rare malignancy that harbors a dismal prognosis in advanced stages. Mitotane is approved as an orphan drug for treatment of ACC and counteracts tumor growth and steroid hormone production. Despite serious adverse effects, mitotane has
Christina Bothou et al.
Cancers, 13(16) (2021-08-28)
Current systemic treatment options for patients with adrenocortical carcinomas (ACCs) are far from being satisfactory. DNA damage/repair mechanisms, which involve, e.g., ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia/Rad3-related (ATR) protein signaling or ribonucleotide reductase subunits M1/M2 (RRM1/RRM2)-encoded ribonucleotide reductase (RNR) activation, commonly contribute
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）